No Data
No Data
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Keros Therapeutics(KROS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return o
Express News | Keros Therapeutics Appoints Jean-Jacques Bienaimé to Its Board of Directors
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.